M-701 is under clinical development by Wuhan YZY Biopharma and currently in Phase II for Malignant Pleural Effusion. According to GlobalData, Phase II drugs for Malignant Pleural Effusion have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how M-701’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
M-701 is under development for the treatment of malignant ascites caused by colorectal, ovarian and liver cancer and malignant pleural effusion. The drug candidate is a recombinant human-mouse chimeric bi-specific antibody. It is administered through the intraperitoneal and intrathoracic route. It acts by targeting cells expressing epithelial cell adhesion molecule (EpCAM) and CD3.
Wuhan YZY Biopharma overview
Wuhan YZY Biopharma (YZY Biopharma) operates as a biotechnology company that develops medicines for cancer treatment. The company’s product pipeline include Y101D- PD-L1×TGF-ß is fot the treatment of bispecific antibody, Y150-CD38×CD3 is for specific antibody, Y2019 – RBD dimer subunit SARS-CoV-2 vaccine, M802 – HER2×CD3 bispecific antibody, Y400- VEGFxANG2 is for bispecific antibody, M701- relapsed or refractory multiple myeloma, Y101D is for the treatment of colorectal cancer, small cell lung cancer among others. It operates through its research and development lab, process development lab, analytical and quality center and a cGMP clinical production facility. YZY Biopharma is headquartered in Wuhan, Hubei, China.
For a complete picture of M-701’s drug-specific PTSR and LoA scores, buy the report here.